Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.

@article{Socinski2002PhaseIT,
  title={Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.},
  author={Mark A. Socinski and Michael J. Schell and Amy Peterman and Kamal Bakri and Steven Yates and Robert Gitten and Paul W. Unger and Joanna Lee and Ji-Hyun Lee and Maureen Tynan and Martha Anne Moore and Merrill S. Kies},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2002},
  volume={20 5},
  pages={1335-43}
}
PURPOSE To compare four cycles of therapy versus continuous therapy to determine the optimal duration of chemotherapy in advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS Stage IIIB/IV NSCLC patients were randomized to arm A (four cycles of carboplatin at an area under the curve of 6 and paclitaxel 200 mg/m(2) every 21 days) or arm B (continuous treatment with carboplatin/paclitaxel until progression). At progression, all patients on both arms were to receive second-line… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 117 extracted citations

Similar Papers

Loading similar papers…